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Key messages
 Doctor-delivered counselling for IPV survivors led to better perceived support
 
 Counselling also resulted in greater self-efficacy at one-year timepoint
 

























Previous research shows counselling delivered by trained family doctors reduces depression for 
women experiencing intimate partner violence. However, the potential for self-efficacy, doctor 
support and safety enquiry to mediate these effects has not been examined.
Objectives
To assess whether a) women experiencing intimate partner violence and counselled by a trained 
family doctor report greater self-efficacy, perceived doctor support and enquiry about safety than 
those receiving usual care; and b) self-efficacy, doctor support and enquiry mediate effects of 
counselling on depression for these women. 
Methods
Quantitative analysis as part of a process evaluation of data from a cluster randomised controlled 
trial of 272 female intimate partner violence survivors attending 52 Australian primary care
clinics. Intervention group doctors were trained to deliver brief counselling. Comparison group 
doctors received standard intimate partner violence information. Intervention patients were
invited to receive counselling from their trained doctor. Comparison patients received usual care. 
Data were collected at baseline, six, and twelve months. Path analysis tested mediation effects 
from trial arm to depression via self-efficacy, doctor support and safety enquiry at six and twelve 






















At six months, mean perceived doctor support was higher for intervention than comparison 
patients, and mediated depression effect. At twelve months, mean self-efficacy was higher for 
intervention than comparison patients and mediated depression effect. Mediation effects for
doctor enquiry were non-significant.
Conclusions
Counselling by trained family doctors can help increase support and self-efficacy of women who 


















     










Globally, one in four women experiences intimate partner violence (IPV) at some stage in her
lifetime (1). This is of high relevance to health practitioners, given evidence shows IPV 
contributes at least as high a health burden to women of child-bearing age as raised blood 
pressure, tobacco use and obesity (2). Women experiencing IPV are at substantially increased 
risk of physical and psychological health damage, including depression, anxiety, chronic pain, 
gynaecological and general health issues (1). Family doctors are often the first or only point of 
contact for women experiencing IPV, and it is imperative they have the training and referral 
pathways in place to support patients who disclose or are identified as experiencing IPV (3). The
World Health Organization (4), the United States Preventive Taskforce (5), and the National 
Institute for Health and Care Excellence (6) all recommend woman-centred care as a first line
response following identification or disclosure of IPV. However, there have been limited trials to 
further guide family doctors regarding care they should offer women experiencing IPV (3, 7). 
Furthermore, there have been very few process evaluations of IPV trials to assess mechanisms 
through which successful interventions operate. 
A landmark cluster randomised controlled trial (RCT), WEAVE, evaluated the impact of training
family doctors in primary care settings to provide counselling for patients experiencing IPV (8­
10). Women in the intervention group reported increased enquiry about women’s safety and 
decreased depressive symptoms, both pre-specified as secondary outcomes (9). Although pre­
specified effect sizes for primary outcomes (quality of life and safety planning) were not 




















have wide-ranging implications (11). Meta-analyses have shown strong associations between 
IPV and depression (12, 13). These associations can be in either direction, with IPV potentially
leading to depression, and depression increasing risk of IPV victimisation (12, 13). Depression 
may adversely impact an individual’s capacity to recognise abuse, keep themselves and their
children safe, and ultimately escape the abuse.
The Realistic Evaluation model was used to guide a series of process evaluations of the WEAVE
trial (10, 14-18). This model focuses on exploring how outcomes are produced and under what 
circumstances, by examining context, mechanisms and outcome patterns of the trial (14). For a
list of previous WEAVE process evaluation papers see Supplement. The current paper is the next 
in this series of process evaluations, focusing on the intermediate mechanisms through which the 
WEAVE counselling intervention reduced depressive symptoms for patients experiencing IPV.
Elucidating processes by which an intervention results in improved outcomes is essential for 
guiding successful replication or upscaling of interventions (19-21). One way of investigating
intermediate processes is through use of path analysis incorporating mediation effects (22). This 
quantitative approach to process evaluation is underutilised, as process evaluations often focus 
on qualitative or univariate methodologies (22). 
Increased self-efficacy and perceived support are two variables which have contributed to or 
mediated reduced depression in studies with other patient groups (23-25). The Psychosocial 
Readiness Model (26) also identifies survivors’ perceptions of support, self-efficacy and 
readiness to change as factors that may influence positive outcomes for IPV survivors. Based on 





















increase women’s perception of support and lead to positive changes in self-efficacy and 
readiness to change, and that these ‘internal’ changes would collectively lead to reduced 
depression (10). Here, we aim to assess a) whether brief counselling delivered by family doctors 
increases self-efficacy and perceived doctor support among women who experienced IPV and b) 
whether self-efficacy, doctor support and safety enquiry mediate reduced depressive symptoms 
for these women.
Method
Study design and participants
The WEAVE study was a cluster RCT in Victoria, Australia, involving 52 family doctors (at 
separate clinics) and 272 female patients who experienced fear of a partner in the past twelve 
months (9, 10). Participants were eligible if they were aged 16 to 50 years, attended the study
doctor in the past 12 months, and reported feeling afraid of their partner or ex-partner in the past 
12 months in a health screening survey sent to all of the doctors’ female patients (9, 10). The trial 
conformed to CONSORT guidelines and was approved by The University of Melbourne’s 
Human Research Ethics Committee. Full details of the trial are published elsewhere, including
CONSORT flow diagram, sample size calculations, participant characteristics, and primary
outcomes (9, 10). Participant characteristics were similar across intervention and comparison 
arms (9). Mean patient age was 37.9 (SD = 8.8) in intervention and 39.1 (SD = 7.3) in 
comparison group. One-hundred-and-forty-four (53%) patients lived with a partner, 159 (59%) 


















    
 
 
received a government pension as their main source of income, and 257 (94%) spoke English as 
their first language (9).
As described elsewhere (9), 25 doctors were randomly allocated to the intervention and 27 
doctors to the comparison arm. Their patients were also allocated to the corresponding arm, 
resulting in 137 women in the intervention and 135 in the comparison arm. In brief, doctors in 
the intervention group participated in “Healthy Relationships” training designed to help them 
deliver a brief, woman-centred counselling intervention to women fearful of a partner (8). 
Following randomisation, women in the intervention group were invited to attend up to six
sessions of brief counselling for relationship and emotional issues by their trained doctor at no 
cost (9). The counselling included listening, validating women’s experiences and feelings, 
assessing safety and readiness for change, and supporting decision-making to improve self-
efficacy (8). Doctors in the comparison group received a basic IPV information pack and 
delivered care as usual. All participants received a list of relevant resources. Sixty-seven (49%) 
intervention group women attended at least one WEAVE counselling session (see Supplement 
for further details).
Measures and data collection
Data were collected from patients via postal surveys at baseline, six and twelve months, as 
described in detail elsewhere (9). 
1.	 Depression was measured using the Hospital Anxiety and Depression Scale (HADS) 












   
 
  
   
 
 
   
  
 
Items are self-reported on a four-point Likert scale from zero to three. Total depression
scores can range from zero to 21. Scores greater than seven represent possible depression. 
2.	 Self-efficacy was measured using the General Self-Efficacy Scale (GSES) (28), which 
consists of 10 items, self-reported on a four-point Likert scale from one to four. Total 
self-efficacy scores range from 4 to 40. 
3.	 Perceived doctor support was assessed by asking participants to mark to what degree they
felt supported by the doctor on a visual analogue scale ranging from 0 (completely
unsupported) to 100 (completely supported). 
4.	 Patients were asked whether the trial doctor enquired about their safety during the past 
six months (yes / no).
5.	 Severity of IPV was included in these analyses as a control variable, as IPV could 
influence depressive symptoms, doctor enquiry and self-efficacy. Severity of IPV was 
measured using the Composite Abuse Scale (CAS) (29). The CAS asks respondents to 
rate how often they experienced 30 IPV behaviours indicative of physical abuse, 
emotional abuse, harassment, or severe combined abuse. Item responses range from 0 
(never) to 5 (daily). Total CAS scores can range from 0 to 150.
Data analysis
Path analyses were conducted using full information maximum likelihood estimation with robust 
standard errors in MPlus Version 7 (30). Main analyses followed intention-to-treat principles, 
including all available data from all participants, including intervention group participants who 
did not attend counselling. However, supplementary subgroup analyses were also conducted to 

















(Supplement). Across all analyses, missing data was assumed to be missing at random and 
handled within the full information maximum likelihood model. Trial arm (intervention versus 
comparison) was entered as the predictor variable. Depression scores at six and twelve months 
were entered as outcome variables. Self-efficacy, perceived doctor support, and doctor enquiry
about safety at six and twelve months were entered as proposed mediators. Analyses adjusted for 
women attending same doctor (cluster effect) and rural versus urban stratification. Analyses also 
controlled for level of abuse at each time-point, and for baseline levels of depression, perceived 
doctor support, and doctor enquiry. A baseline measure of self-efficacy was not collected and 
was therefore unable to be included in the model. Given prior research shows an association 
between self-efficacy and depression (31, 32), depression was used as a proxy control variable
for self-efficacy. Baseline depression was also the control variable for depression outcomes. 
Total, direct and indirect effects were calculated for each potential pathway in the model. The
model was refined by excluding mediation paths that made no statistically significant 
contribution to the model, and by assessing fit indices. Fit indices assessed included Root Mean 
Square Error of Approximation (RMSEA), Comparative Fit Index (CFI) and Tucker Lewis index
(TLI) (33). RMSEA values below .06 and CFI and TLI values above .90 were regarded as 
providing good model fit (33). It should be noted that indirect mediation effects are routinely of 
smaller magnitude than direct effect sizes, and this magnitude cannot be assessed in the same 
manner as direct effects (34).
To test mediation effects, paths from mediators to outcomes needed to be specified as 
unidirectional paths (22, 35). A priori predictions based on the Psychosocial Readiness Model 

























paths in this direction was also consistent with the process evaluation aims of the study, as we
were primarily interested in explaining variance in the depression outcomes. Feedback loops
were unable to be tested as part of the final model due to ratio of participants to parameters being
too low for this level of complexity. As an alternative, for each mediation path found, separate ad 
hoc analyses were undertaken to test reverse paths.
Results
The six-month survey was completed by 94/137 intervention and 99/135 comparison women. 
The twelve-month survey was completed by 96/137 intervention and 100/135 comparison 
women. Flow of participants through the trial, and reasons for non-return of surveys, are
described elsewhere (9). Table 1 shows rates of complete and missing data for each variable of
interest in path analyses, along with baseline, six-month and twelve-month descriptive statistics 
for each variable. Figure 1 shows mediation paths that contributed to reduced depression at six
and twelve months. Table 2 shows the total, direct and indirect effects for these paths. Safety
enquiry at 6 months was also retained in the model due to its contribution to a statistical 
suppression effect, explained in Supplement (35). The final model (Figure 1) showed very good 
fit (RMSEA = .046; CFI = .962; TLI = .944) (33) and explained 42.1% of variance in depressive

























At six months, perceived doctor support was higher for women in the intervention than 
comparison group (see Table 1 and path b in Figure 1 and Table 2). The standardised coefficient 
for this association was of moderate magnitude (Table 2) (33). Higher perceived doctor support 
was, in turn, associated with lower depression at six months, again with a standardised 
coefficient of moderate magnitude (see path e, Figure 1 and Table 2). Ad hoc analyses showed 
no significant effect in the opposite direction (B [SE] = 0.32 [0.53], β = .04 [.07], p = 0.547). The
indirect mediation effect from group assignment to depression via perceived support was 
statistically significant (see path b*e in Figure 1 and Table 2). In other words, at six months, the
lower depression experienced by the intervention group could be partially explained by higher 
doctor support, when compared to the comparison group, although direct causation cannot be
inferred. Doctor support at six months continued to have a mediation effect on depression at 
twelve months, via its relationship with depression at six months (see path b*e*i, Figure 1 and 
Table 2). At twelve months, perceived doctor support was excluded from final model, as there
was no significant difference between groups on this variable at this time-point, when using
intention-to-treat analyses (see Table 1; mean difference, controlling for baseline = -0.69, SE =
3.71, p = .852; see Supplement for supplementary findings).
At six months, more women in the intervention group were asked by the WEAVE doctor about 
their safety than women in comparison group (see Table 1 and path c in Figure 1 and Table 2). 












    
  
    
  
Controlling for this suppression effect required specification of a unidirectional path from doctor 
enquiry to depression in the model, rather than free estimation of a bidirectional path (35)
(Supplement). Although the unidirectional path did not reach statistical significance, its inclusion 
was necessary to allow clear estimation of the direct effect between doctor support and 
depression (Supplement). The difference between groups on doctor enquiry continued at twelve 
months (see Table 1). However, this path at twelve months did not contribute to mediation or 
suppression effects and therefore was not retained in the model.
At twelve months, mean self-efficacy scores were higher for women in the intervention than 
comparison group, and the standardised coefficient for this association was of moderate 
magnitude (see Table 1 and path d, Figure 1 and Table 2). Higher self-efficacy scores were, in 
turn, moderately associated with lower depression (see path g, Figure 1 and Table 2). Self-
efficacy mediated the effect from group to depression at twelve months, as indicated by a
significant indirect effect (see path d*g, Figure 1 and Table 2). In other words, at twelve months, 
higher self-efficacy associated with the intervention could partially explain lower depression 
experienced by the intervention group. It should be noted, however, that this effect may be
bidirectional, and that causation cannot be inferred. Ad hoc analyses also showed a significant 
path from depression to self-efficacy at 12 months (B [SE] = -0.73 [0.11], β [SE] = -.56 (.08), p
< .001). The indirect mediation effect from group to self-efficacy via depression at twelve 
months was also statistically significant (B [SE] = 0.90 [0.36], β [SE] =.15 [.06], p = .012). At 
six months, self-efficacy was excluded from the model, as there was no significant difference
between groups on this variable at this time-point (see Table 1; mean difference [SE] = 0.69 




















This process evaluation study of a landmark RCT of brief counselling for IPV found that a
woman’s perception of the support received from her family doctor and her level of self-efficacy
play a mediating role in reducing depressive symptoms. Firstly, relative to the comparison group,
women in the intervention group felt more supported by the WEAVE doctor at six months and 
had higher mean self-efficacy scores at twelve months. Both variables were targeted as part of an 
a priori pathway to improved depression. These group differences mediated the lower depression 
scores for intervention group women observed at 6 and 12 months, although unidirectional 
causation cannot be inferred. Although more intervention than comparison women were asked 
about their safety by their family doctor at six and twelve months, this enquiry did not directly
mediate depression outcomes. The overall findings of this process evaluation are consistent with 
the WEAVE trial hypothesis that an intervention focused on providing support and enhancing
self-efficacy for women would facilitate improved mental health, in this case improved 
depression (10, 36).
Doctors in the intervention arm of the WEAVE trial were trained to engage in active listening, 
inquiring about needs, validating experiences, enhancing safety and supporting decision-making, 
along with other aspects of patient-centred care (8). The current findings suggest this approach 
was more effective than usual care in helping women feel supported by the doctor, particularly





















Intervention group women who attended counselling continued to feel more supported than the
control group at twelve months (Supplement).
The mediating effect doctor support had on depression at six-months is consistent with prior
research in other patient groups, which show perceived support from a therapeutic relationship 
can help alleviate depression (24). A mixed-methods process-evaluation regarding which 
intervention group patients attended WEAVE counselling sessions and why, showed that good 
doctor communication and supportiveness can also help patients feel comfortable attending brief 
relationship counselling in the first place (17). Thus, the benefits of enhancing doctor
supportiveness may be two-fold, both encouraging IPV survivors to attend brief relationship 
counselling, and helping facilitate improved depression outcomes when they do. It should be 
noted, however, that the effect size for the association between doctor support and depression at 
six months was small, and that this association did not continue at twelve months, even for
women who attended the counselling. Counselling was only offered during the first six months 
post-baseline, thus any impact related support had on depression may have attenuated by the
twelve-month timepoint.
The relationship at twelve months between patient-centred counselling and increased self-
efficacy, and between increased self-efficacy and reduced depression, is also consistent with 
prior research in other patient groups (23, 25). An explanation for the reduced depression via 
self-efficacy is that believing in one’s ability to change a situation may circumvent intrusive
traumatic thoughts, replacing them with a sense of having the capacity to change the situation 













      








   
of control and a sense of powerlessness and hopelessness, as the perpetrator engages in 
continued efforts to undermine the survivor’s confidence and agency (37). Improvements in self-
efficacy and depression may help a survivor gain agency in preparing for, implementing or 
maintaining their goals (38). Improved doctor support, enquiry about safety and self-efficacy
may also have wider positive consequences, beyond those measured in the WEAVE trial (23, 
39).
Further research is needed to explore why the effect for self-efficacy was significant at twelve 
months but not six months. One possible explanation is that self-efficacy may have taken some
time to fully develop following the counselling invitation (38). This explanation would be
consistent with theories of self-efficacy development, given initial steps toward desired change
can be a catalyst for increased self-efficacy over time, facilitating a person’s belief in their ability
to mobilise even further change (23, 39). In the case of IPV, this change could include, for 
example, putting parts of a safety plan into action, seeking out additional supports, or practicing
strategies to reduce intrusion of traumatic memories; actions which intervention group doctors 
were trained to support (8). It could take participants time to put their desired actions into place, 
and for these actions to facilitate further self-efficacy development. This possible explanation is 
difficult to fully assess, given the self-efficacy measure was not collected at baseline. Future
research could further explore temporal and contextual aspects of self-efficacy development 
following counselling for IPV survivors.
One challenge in interpreting these self-efficacy findings is that there is little prior literature



















this difference would have a real impact on the lives of IPV survivors. Nonetheless, clinical 
expectations can be guided by converting the standardised effect size into a “number needed to 
treat” (NNT) value (40), and by examining how the mean difference between groups could 
translate into GSES responses. The standardised difference between groups on self-efficacy at 12 
months was around a third of a standard deviation (Cohen’s d = β = 0.32). Conversion to NNT, 
shows we would expect to invite six patients for counselling in order to have one more success 
(where success is defined as having a better self-efficacy score than a randomly selected patient 
receiving usual care) (40). Examination of GSES content suggests that the two-point mean 
adjusted score difference between groups could have possible real-life implications for an IPV 
survivor’s wellbeing (see further explanation in Supplement). The mediating effects of self-
efficacy on depression (and of depression on self-efficacy), also suggest this difference may have
some clinical relevance. However, a great deal more research is needed to test thresholds for
clinical meaning of GSES score differences.
Overall limitations of the WEAVE trial have been discussed elsewhere (9, 17). However, there
are some additional limitations specific to these analyses. The stratified and clustered nature of 
the current data set limited the complexity of paths that could be estimated in the current model. 
Future studies may be able to explore these paths further, using larger sample sizes, and 
alternative sampling methods. Supplementary, ad hoc subgroup analyses undertaken in this study
showed somewhat higher effect sizes when excluding women in the intervention group who did 
not attend counselling. This suggests overall effects of the intervention were attenuated by low 
uptake of counselling intervention sessions. Larger sample sizes would also allow effects to be




















performed. An interview-based process evaluation of WEAVE identified several barriers that 
prevented some women attending counselling sessions, and these could be addressed in future
research (17). Further research could also focus on whether women benefit from follow-up 
counselling sessions, or other interventions that target improvements in self-efficacy. As the
current sample had a low proportion of unemployed women and primarily included women who 
spoke English as their first language, further research is needed to assess whether the results of 
this study can be generalised to more culturally and linguistically diverse groups. The IPV field 
urgently needs process evaluations alongside further trials in primary care as currently the 
number of trials are few (7).
The process evaluation analysis presented here adds to the dearth of research on the mechanisms 
through which complex interventions operate, particularly in the IPV field (7, 41). The current 
findings show that raising practitioner supportiveness and patient self-efficacy should be
important components of interventions targeting improved depression for women experiencing
IPV. Interventions that do not focus on these variables may be less effective in achieving reduced 
levels of depression, especially in primary health care settings. The Psychosocial Readiness 
Model (26) can provide a sound theoretical framework for developing IPV interventions, given 
its focus on support and self-efficacy, along with awareness, and is currently being used in an 
online healthy relationship and safety decision aid trial (42).
In conclusion, these findings suggest that woman-centred counselling delivered by family
doctors trained to respond to IPV can help a survivor feel supported by their doctor and increase






    
depressive symptoms of women experiencing IPV. IPV interventions which aim to improve
depression outcomes should therefore include an emphasis on enhancing practitioner 
supportiveness and patient self-efficacy. Given the high prevalence of IPV among female
primary care patients, family doctors have an important role in reducing the mental health burden 
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Table 1. Data completeness and descriptive statistics for doctor enquiry, depression, perceived support from doctor, self-efficacy and 
Compositive Abuse Scale for women experiencing fear of a partner or ex-partner enrolled in the WEAVE trial (n = 272).
Intervention
n missing n complete n (%)
Comparison
n missing n complete n (%)
Doctor enquiry about safety
Baseline 1 136 17 (12.50) 2 133 19 (14.29)
6 months 44 93 30 (32.26)a 39 96 12 (12.50)a 
12 months 43 94 19 (20.21)b 36 99 11 (11.11)b 
n missing n complete Mean (SD) n missing n complete Mean (SD)
Depression
Baseline 1 136 7.21 (4.31) 1 134 7.65 (4.20)
6 months 43 94 6.15 (5.02) 37 98 6.95 (4.27)
12 months 41 96 6.19 (4.73) 36 99 7.63 (4.65)
Perceived support from doctor
Baseline 5 132 58.01 (28.90) 5 130 60.90 (27.20)
6 months 51 86 50.26 (38.50) 43 92 35.35 (34.92)




44 93 29.27 (5.99)
41 96 30.17 (6.07)
42 93 28.58 (5.52)
37 98 28.50 (6.10)
Composite Abuse Scale
Baseline 2 135 20.99 (21.60) 3 132 18.49 (17.72)
6 months 44 93 12.89 (17.71) 41 94 11.38 (15.68)
12 months 44 93 13.68 (21.91) 39 96 10.01 (14.06)
Note. Doctor enquiry about safety = whether trial doctor asked woman about her safety in the past six months, as reported by the woman (binary variable: yes/no; 
denominator includes all women who returned the survey, even if they had not visited the trial doctor in the past 6 months); Perceived support from doctor = how
supported woman felt by trial doctor in the past six months (rated on visual analogue scale from 0 to 100); Self-efficacy = General Self-Efficacy Scale score (not 
measured at Baseline); Depression = Depression score on Hospital and Anxiety Depression Scale.
aWhen denominator only includes women who attended trial doctor between baseline and six months: Intervention = 44.12%, Comparison = 18.03%; When numerator




              
            
includes women who attended trial doctor between six and twelve months: Intervention = 30.16%, Comparison = 18.64%; When numerator also includes women who





   
      
                
                 
                
                 
                 
                 
                  
                  
                 
                 
                  
                  
                 
                 
                  
                    
                     
 
             
                      
                   
          
                  
          
   
Table 2. Total, direct and indirect effects from trial group (intervention or comparison) to depression at six and twelve months for women 
experiencing fear of a partner or ex-partner enrolled in the WEAVE trial (n = 272)a 
Path
Total effect
B (SE) β (SE) p
Direct effect
B (SE) β (SE) p
Indirect effect
B (SE) β (SE) p
a: Support (6m) Enquiry (6m) 2.60 (0.57) .51 (.07) <.001 2.60 (0.57) .51 (.07) <.001 - - -
b: Group Support (6m)
c: Group Enquiry (6m)
d: Group Self-efficacy (12m)
15.59 (4.76) .43 (.13)
0.20 (0.04) .48 (.10)




15.59 (4.76) .43 (.13)
0.20 (0.04) .48 (.10)










e: Support (6m) Dep (6m)
f: Enquiry (6m) Dep (6m)
g: Self-efficacy (12m) Dep (12m)
-0.02 (0.01) -.15 (.05)
1.27 (0.06) .11 (.06)




-0.02 (0.01) -.15 (.05)
1.27 (0.06) .11 (.06)










h: Group Dep (6m)
b*e: Group Support (6m) Dep (6m)
c*f: Group Enquiry (6m) Dep (6m)
-1.07 (0.46) -.23 (.10) .019 -1.03 (0.53) -.22 (.11) .051
-0.29 (0.14) -.06 (.03)
0.25 (0.15) .05 (.03)
.032
.098
i: Dep (6m) Dep (12m) 0.35 (0.06) .35 (.07) <.001 0.35 (0.06) .35 (.07) <.001 - - -
j: Group Dep (12m)
d*g: Group Self-efficacy (12m) Dep (12m)
h*i: Group Dep (6m) Dep (12m)
b*e*i: Group Support (6m) Dep (6m) Dep (12m)
c*f*i: Group Enquiry (6m) Dep (6m) Dep (12m)
-1.75 (0.50) -.37 (.10) <.001 -0.76 (0.37) -.16 (.08) .038
-0.62(0.28) -.13 (.06)
-0.36 (0.19) -.08 (.04)
-0.10 (0.05) -.02 (.01)





Note. B = Unstandardized B coefficient; β = standardised beta coefficient; SE = standard error; 6m = six months; 12m = twelve months; Group = Intervention or
comparison group (intervention group was coded as 1, and comparison group was coded as 0); Enquiry = whether WEAVE doctor asked woman about her safety in the 
past six months, as reported by the woman (binary variable: yes/no); Support = how supported woman felt by WEAVE doctor in the past six months (rated on visual 
analogue scale); Self-efficacy = General Self-Efficacy Scale score; Dep = Depression score on Hospital and Anxiety Depression Scale.
aEffects are presented as unstandardized B weights and standardized β weights, with standard errors in parenthesis, adjusted for outcome and mediation measures at 
baseline, Composite Abuse Scale at each time point, cluster (woman’s doctor) and practice location. Where mediation is present the specific indirect effect is 










           
           
             
      
        




Figure 1. Model of paths from trial group to depression at six and twelve months for women 
experiencing fear of a partner (n = 272). Estimates in figure are standardised direct effects, with 
standard errors in round parenthesis. Where total effects are different to direct effects, these are
given in square brackets. See Table 1 for all total, direct and indirect effects and significance
levels in model.
Note. Group = Intervention or comparison group; 6m = six months; 12m = twelve months; Doctor support = how
supported woman felt by trial doctor in the past six months (rated on visual analogue scale); Doctor enquiry = 
whether trial doctor asked woman about her safety in the past six months, as reported by the woman (binary
variable: yes/no); Self-efficacy = General Self-Efficacy Scale score; Depression = Depression score on Hospital and
Anxiety Depression Scale. Dotted line represents a total effect not significantly different from zero (but that 





























    










Previous WEAVE process evaluation papers
Thus far, the WEAVE process evaluations have included analysis of screening and baseline
characteristics (1, 2), mixed-methods analysis of barriers and facilitators to attending the 
counselling intervention, drawing on the Theory of Planned Behaviour (3), exploration of
participants’ experiences of the intervention (3), and mixed-methods analysis of positive and 
negative consequences of trial participation (4).
Dates of recruitment and data collection
Doctors and their patients were recruited and randomised between 31 January 2008 and 18 June
2010. Six-month data collection occurred between 26 August 2009 and 24 June 2011, and 
twelve-month data collection between 18 March 2010 and 24 November 2011 (5).
Number of participants in intervention and comparison group who attended trial doctor
In total, 90 (66%) intervention group women attended at least one appointment with their 
WEAVE trial doctor between baseline and twelve months, with 23 (17%) attending five or more
appointments (5, 3). For 67 (49%) of the intervention group women at least one of these
appointments was a WEAVE counselling session (mean number of counselling sessions attended 
= 2.4, SD = 1.7, range = 1 to 6). Seventy-nine (59%) comparison group women attended at least 
one general appointment with their WEAVE trial doctor for usual medical care, with 22 (16%) 
attending five or more appointments.
Supplementary subgroup analyses
Supplementary, ad hoc subgroup analyses were conducted to assess effects when excluding
women in the intervention who did not attend counselling. These supplementary analyses were
conducted using the SUBPOPULATION command in MPlus Version 7 (6), and fitting the same
path model as presented in the main text.
It was not possible to treat counselling attendance as a moderator variable in the current analyses, 
as there was no meaningful way in which to divide the comparison group into two equivalent 
subgroups. Hence the need to conduct this subgroup analysis separately.
Results for these supplementary analyses are reported in Table S1 (descriptive statistics) and 
Table S2 (total, direct and indirect effects for paths in the model), on the following pages. Effect 
sizes tended to be larger when excluding intervention group women who did not attend 
counselling. Supplementary analyses also showed that, when excluding counselling non-
attenders from the intervention group, there was a significant association between group and 
doctor support at twelve-months, but not between doctor support and depression (Table S2). 









   
         
           
          
           
           
         
         
          
           
           
           
          
           
           
         
           
           
         
          
           
           
 
                   
                    
                 
                 
                 
                 
Table S1. Descriptive statistics of outcomes, mediators and control variables when excluding women in the intervention group who did not attend 
counselling intervention (total n for this table = 202)
Intervention
n missing n complete n (%)
Comparison
n missing n complete n (%)
Doctor enquiry about safety
Baseline 1 66 10 (15.15) 2 133 19 (14.29)
6 months 16 51 28 (54.90) 39 96 12 (12.50)a 
12 months 15 52 15 (28.85)b 36 99 11 (11.11)b 
n missing n complete Mean (SD) n missing n complete Mean (SD)
Depression
Baseline 1 66 8.11 (4.33) 1 134 7.65 (4.20)
6 months 15 52 6.06 (4.70) 37 98 6.95 (4.27)
12 months 14 53 5.83 (4.72) 36 99 7.63 (4.65)
Perceived support from doctor
Baseline 3 64 62.17 (27.82) 5 130 60.90 (27.20)
6 months 18 49 73.96 (28.73) 43 92 35.35 (34.92)




16 51 29.43 (5.88)
14 53 30.51 (6.15)
42 93 28.58 (5.52)
37 98 28.50 (6.10)
Composite Abuse Scale
Baseline 1 66 20.58 (17.39) 3 132 18.49 (17.72)
6 months 15 52 11.79 (14.86) 41 94 11.38 (15.68)
12 months 16 51 12.02 (19.21) 39 96 10.01 (14.06)
Note. Doctor enquiry about safety = whether trial doctor asked woman about her safety in the past six months, as reported by the woman (binary variable: yes/no); Perceived support 
from doctor = how supported woman felt by trial doctor in the past six months (rated on visual analogue scale from 0 to 100); Self-efficacy = General Self-Efficacy Scale score (not 
measured at Baseline); Depression = Depression score on Hospital and Anxiety Depression Scale. aWhen denominator only includes women who attended trial doctor between
baseline and six months: Comparison = 18.03%; When numerator also includes women who told the doctor about their safety without first being asked: Intervention = 43 (82.69%),
Comparison = 21 (33.87%). bWhen denominator only includes women who attended trial doctor between six and twelve months: Intervention = 34.09%, Comparison = 18.64%; 








      
                
                 
                
                 
                 
                 
                  
                  
                 
                 
                  
                  
                 
                  
                  
                    
                     
                   
                    
 
                
                      
               
                  
               
Table S2. Total, direct and indirect effects from trial group (intervention or comparison) to depression at six and twelve months, when excluding
women in the intervention group who did not attend counselling intervention (total n for this table = 202)a 
Path
Total effect
B (SE) β (SE) p
Direct effect
B (SE) β (SE) p
Indirect effect
B (SE) β (SE) p
a: Support (6m) Enquiry (6m) 3.69 (1.2) .33 (.09) <.001 3.69 (1.2) .33 (.09) <.001 - - -
b: Group Support (6m)b 
c: Group Enquiry (6m)b 
d: Group Self-efficacy (12m)
27.08 (5.96) .74 (.16)
0.26 (.08) .59 (.17)




27.08 (5.96) .74 (.16)
0.26 (.08) .59 (.17)










e: Support (6m) Dep (6m)
f: Enquiry (6m) Dep (6m)
g: Self-efficacy (12m) Dep (12m)
-0.02 (0.01) -.17 (.06)
1.72 (0.72) .17 (.07)




-0.02 (0.01) -.17 (.06)
1.72 (0.72) .17 (.07)










h: Group Dep (6m)
b*e: Group Support (6m) Dep (6m)
c*f: Group Enquiry (6m) Dep (6m)
-1.43 (0.47) -.33 (.11) .002 -1.36 (0.72) -.31 (.16) .056
-0.78 (0.30) -.18 (.07)
0.71 (0.34) .16 (.08)
.009
.036
i: Dep (6m) Dep (12m) 0.36 (0.08) .34 (.08) <.001 0.36 (0.08) .34 (.08) <.001 - - -
j: Group Dep (12m)
d*g: Group Self-efficacy (12m) Dep (12m)
h*i: Group Dep (6m) Dep (12m)
b*e*i: Group Support (6m) Dep (6m) Dep (12m)
c*f*i: Group Enquiry (6m) Dep (6m) Dep (12m)
-2.29 (0.55) -.49 (.11) <.001 -0.98 (0.46) -.21 (.10) .034
-0.80 (0.33) -.17 (.07)
-0.50 (0.30) -.11 (.06)
-0.28 (0.11) -.06 (.03)





Group Support (12m)c 
Group Enquiry (12m)c 
7.62 (2.99) .28 (.11)
0.17 (0.06) .45 (.16)
.011
.004
7.62 (2.99) .28 (.11)







Note. B = Unstandardised B coefficient; β = standardised beta coefficient; SE = standard error; 6m = six months; 12m = twelve months; Group = Intervention or comparison group
(intervention group was coded as 1, and comparison group was coded as 0); Enquiry = whether WEAVE doctor asked woman about her safety in the past six months, as reported by
the woman (binary variable: yes/no); Support = how supported woman felt by WEAVE doctor in the past six months (rated on visual analogue scale); Self-efficacy = General Self-
Efficacy Scale score; Dep = Depression score on Hospital and Anxiety Depression Scale. aEffects are presented as unstandardised B weights and standardised β weights, with




                 
                  
                 
              
  
Where mediation is present the specific indirect effect is significantly different to zero. bPaths from group to doctor support at six months were fitted separately for this analysis due 
to inflated standardised estimates; these paths remain significant when comparison group only includes women who visited trial doctor. cDoctor support and doctor enquiry at twelve 
months were excluded from the overall mediation model as they had no significant relationship with depression, and therefore did not contribute to any mediation effects in the 









   








          
           
 
     
 
              
               
     
              





   
 
Further explanation of statistical suppression in the model
Statistical suppression can occur when three variables are associated with each other but one 
of the associations is negative whereas the other two are positive (7). As an example, 
consider a situation where x is negatively associated with y, while a third variable, c, is 
positively associated with both x and y (Figure S1, diagram i). As a result, the direct path 
from x to y is negative, whereas the indirect path from x to y, via c is positive. If c is not 
controlled for in the model, the indirect, positive path will obscure the direct, negative path 
(Figure S1, diagram ii). Adjusting for the positive variance associated with c, by including c
in the model, allows the negative, direct effect from x to y to be clearly estimated (Figure S1, 
diagram iii). In some models, suppression can exist even when not all paths in the model are
statistically significant (7).
i)
ii) iii)               
Figure S1. Diagrammatic example of statistical suppression
i) Example of path where statistical suppression is present. The direct path from x to y is negative, however the 
indirect path from x to y, via c is positive. The indirect, positive path will need to be controlled for in the model,
so that the direct, negative path can be clearly estimated.
ii) The positive variance c shares with x and y may obscure the negative association between x and y.
iii) When positive variance associated with c is controlled for, the negative association between x and y
becomes clearer.
In the current model, at six months, doctor support had a negative association with 
depression. However, doctor enquiry had a positive association with both doctor support and 
depression (see paths e, a and f, Figure 1 and Table 1). This created a statistical suppression 
effect whereby the trend toward a positive relationship between doctor enquiry and 
depression obscured the negative relationship between doctor support and depression (Figure





















                  





            
        
           
     
 
             
             
         
 
          
        
    
  
months, allowing the negative association between doctor support and depression to be 
observed (Figure S2, diagram ii). In other words, doctor enquiry was included in the model as 
a suppressor variable, defined as “a variable which increases the predictive validity of another 
variable (or set of variables) by its inclusion in a regression equation…” (8). 
When allowing free estimation of parameters in the model, the bidirectional association 
between doctor enquiry and depression at 6 months was positive and statistically significant 
(β = .12, p = .047). This suggests that doctors were more likely to ask about safety if the
patient was experiencing depressive symptoms. However, controlling for doctor enquiry as a
suppression variable required specification of a unidirectional path from doctor enquiry to 
depression in the model, rather than free estimation of a bidirectional path (7). Although this
unidirectional path did not reach statistical significance (Table 2, main text), its inclusion was 
necessary to allow clear estimation of the direct effect between doctor support and depression 
(Figure S2).
i) ii)       
Figure S2. Simplified diagrams illustrating statistical suppression in the WEAVE path model 
at 6 months
ii) When not controlling for doctor enquiry, the positive variance doctor enquiry shared with doctor support and
depression obscured the negative association between doctor support and depression.
iii) When positive variance associated with doctor enquiry was controlled for, the negative association between
doctor enquiry and depression became clearer.
Notes. Support = how supported woman felt by WEAVE doctor in the past six months (rated on visual analogue 
scale); Enquiry = whether WEAVE doctor asked woman about her safety in the past six months, as reported by
the woman (binary variable: yes/no); Depression = score on Hospital and Anxiety Depression Scale.
This figure is for illustrative purposes only, and does not attempt to represent actual proportions of shared and
unique variance, nor the complexity of regression analysis. Theoretically, a negative association cannot be 
















    
  
 
     
 
 
    
 





Further examination of GSES score differences in relation to GSES content
When accounting for clustering effects, stratification and control variables, there was a two-
point mean difference between groups on the GSES (see Table 2, main text). This difference
should be viewed in the context of the GSES being a relatively short scale (10 items), with 
only four response options available on each item (four-point Likert scale from 1 = “Not at all 
true” to 4 = “Exactly true”) (28).
Below are some examples of what a a two-point difference on the GSES could represent, in 
terms of item content. A two-point difference on the GSES could be equivalent to the
difference between:
	 agreeing versus disagreeing with the item, “I can always manage to solve difficult 
problems if I try hard enough” (i.e. response of “exactly true” versus “hardly true” or 
“moderately true” versus “not at all true”);
	 agreeing versus disagreeing with the item, “I am confident that I could deal efficiently
with unexpected events” (i.e. response of “exactly true” versus “hardly true” or 
“moderately true” versus “not at all true”);
	 responding “moderately true” instead of “hardly true” to both of the above two items. 
Taking these examples further, it is conceivable that feeling able, rather than unable, to solve
difficult problems or deal with unexpected events could have real-life implications for an IPV 
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